Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNY4 pseudogene 20 (RNY4P20) is a non-coding pseudogene in the human genome, annotated as a sequence highly similar to the functional RNY4 gene but lacking the ability to encode a functional Y RNA[5]. Pseudogenes such as RNY4P20 arise from duplication or retrotransposition of functional genes—often carrying sequence similarity but usually nonfunctional due to mutations or lack of regulatory elements[4]. There is currently no evidence that RNY4P20 itself is transcribed or functional, nor is it considered a therapeutic target. The functional RNY4 gene, by contrast, produces a Y RNA that participates in ribonucleoprotein complexes (notably the Ro complex), has a role in RNA quality control, and is being investigated as a biomarker in certain cancers[1][3]. There are no clinical interventions, drugs, or biomarker applications directly associated with the RNY4P20 pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNY4 pseudogene 20 (RNY4P20).